Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art

Despite recent advances in ovarian cancer (OC) treatment, including the introduction of bevacizumab and PARP-inhibitors, OC remains a lethal disease. Other therapeutic options are being explored, such as immunotherapy (IT), which has been proved effective in many solid tumors. Findings about tumor-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Provinciali, Nicoletta, Greppi, Marco, Pesce, Silvia, Rutigliani, Mariangela, Briata, Irene Maria, Buttiron Webber, Tania, Fava, Marianna, DeCensi, Andrea, Marcenaro, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806340/
https://www.ncbi.nlm.nih.gov/pubmed/36601114
http://dx.doi.org/10.3389/fimmu.2022.1094017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806340/
https://www.ncbi.nlm.nih.gov/pubmed/36601114
http://dx.doi.org/10.3389/fimmu.2022.1094017

Ejemplares similares